Am J Med Case Rep 8(9): 262-267
PMC: PMC7316192
PMID: 32587886
Management of ST-Elevation Myocardial Infarction in the COVID-19 Era: The Role of Thrombosis and Anticoagulation Strategy
References
- 1. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020.
- 2. Guo T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. Epub 3-27–20.
- 3. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2): 271–280. e278.
- 4. Wood, Shelley“COVID-19 Linked to 38% Drop in US STEMIs.” TCTMD.com, TCTMD.com, 10 Apr. 2020, .[PubMed][Google Scholar]
- 5. Recommendations From the Peking Union Medical College Hospital for the Management of Acute Myocardial Infarction During the COVID-19 Outbreak. Eur Heart J. 2020; March 31:
- 6. Mahmud Ehtisham“ACC, SCAI, ACEP Release Consensus Statement on Management of AMI Patients During COVID-19.” American College of Cardiology, 20 April 2020, .[PubMed][Google Scholar]
- 7. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. [[PubMed]
- 8. Fox Sharon, et al“Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans.” medRxiv preprint. [PubMed][Google Scholar]
- 9. Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020.
- 10. Mega J, Eugene B, Stephen W et al“Rivaroxaban in Patients with a Recent Acute Coronary Syndrome” N Engl J Med 2012; 366: 9–19. [[PubMed][Google Scholar]